← All trials
NCT04691544
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2021
- Primary completion
- Jun 1, 2022
- Completion date
- Dec 31, 2026
- First posted
- Dec 31, 2020
- Last posted
- Dec 31, 2020
- Enrollment
- 450
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University Hospital of North NorwayLead sponsor
- University of OsloCollaborator
- University Hospital of North NorwayOverall official - principal investigator
- Sorlandet Hospital HFCollaborator
- University of BergenCollaborator
- Helse Møre og Romsdal HFCollaborator
- University Hospital of North NorwayOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.